MB-CART20.1 Melanoma

Phase 0 Terminated 9 enrolled Miltenyi Biomedicine GmbH DLR German Aerospace Center · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase l multi-centric, single arm, prospective, open, dose-escalation study in patients with unresectable stage III oder IV melanoma. The trial will include 15 adult patients. The trial is a classic 3+3 design with 1 Log dose increments and maximum 3 dose levels of the intravenously administered MB-CART20.1.

Timeline

Start: 2019-03-08
Primary completion: 2023-01-30
Completion: 2023-01-30

Publications

Aleksandrova K, Leise J, Priesner C, Aktas M, Apel M, Assenmacher M, Burger I, Richter A, Altefrohne P, Schubert C, Holzinger A, Barden M, Bezler V, von Bergwelt-Baildon M, Borchmann P, Goudeva L, Glienke W, Arseniev L, Esser R, Abken H, Koehl U. Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. Front Immunol. 2024 Sep 25;15:1328368. doi: 10.3389/fimmu.2024.1328368. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MB-CART20.1	Cell therapy	100000 cells/kg	Intravenous
Subject	MB-CART20.1	Cell therapy	1e+06 cells/kg	Intravenous
Subject	MB-CART20.1	Cell therapy	1e+07 cells/kg	Intravenous

MB-CART20.1 Melanoma

Summary

Timeline

Publications

Drugs

Indications